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Background. Hyperbaric oxygen (HBO) therapy, which is used for many conditions, may also have immunosuppressive eﬀects
and could be used for prevention or treatment of graft-versus-host disease (GvHD). If HBO is immunosuppressant, then we
hypothesize that HBO therapy will delay the T-cell mediated skin graft rejection. Methods. C57/BL6 black-coated (H2B) mice
received skin graft from CBA (H2D) white-coated mice. Mice were treated with either 19 session of 240 kpa oxygen or 29 session
of 300 kpa oxygen, for 90 minutes. Mice were housed either 4 per cage or separately, to prevent friction and mechanical factors
that may aﬀect graft survival. Skin grafts were assessed daily. Results. There was no diﬀerence in length of graft survival between
mice that received either regimens of HBO therapy and mice that did not receive HBO therapy. Conclusions. HBO therapy, as a
sole agent, did not delay skin graft rejection in a highly immunogenic mouse model.
1. Introduction
Exposure to HBO therapy, at least in rodents, appears to
be immunosuppressant and leads to an anti-inflammatory
eﬀect. Several mechanisms have been proposed; inhibition
of interferon-γ [1], interleukin-1 β, and tumor necrosis
factor α release [2], a temporary drop in the CD4 : CD8
lymphocyte ratio [3], and a decrease of lymphocyte prolifer-
ation [4]. As a result, HBO exposure attenuates the immune
system, increases the susceptibility to respiratory infections
[5, 6], and delays allograft rejection in mice [7–9]. On
the contrary, other reports suggest no immunosuppressant
eﬀect of HBO or even immunostimulant eﬀect in particular
neutrophiles activation [10, 11]. At present, there is a
wide spectrum of indications for HBO therapy. According
to the Undersea and Hyperbaric Medical Society, HBO
therapy is indicated for carbon monoxide poisoning and gas
embolism [12], clostridial myonecrosis [13], compartment
syndrome and other traumatic ischemia with nonhealing
wounds [14], necrotizing soft tissue infections, sepsis, and
others [15–18]. Given the increasing availability of HBO
therapy in recent years and the rarity of serious side eﬀects,
HBO therapy as an immunosuppressant is an attractive
option. Perhaps, HBO therapy could be added to prevent
or to treat GvHD in allogeneic hematopoietic stem cell
transplantation (HSCT). Therefore, our aim was to test
the eﬀect of HBO therapy on the immune system by
measuring the integrity and the duration of skin allo-
geneic graft in mice. Graft rejection is a T-cell mediated
phenomenon, and if HBO therapy is immunosuppressant,
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then exposure to HBO therapy could potentially delay graft
rejection.
2. Materials and Methods
Six-eight week-old black-coated C57/BL6 (H2B) mice, pur-
chased from Jackson Laboratory, received skin grafts from
CBA (H2D) white-coated mice donors. Mice were randomly
assigned to either receive HBO treatment or not (control).
All experiments were approved by the animal facilities
Research Ethics Board, University of Toronto.
Skin grafting was performed accordingly, as previously
described [19]. Briefly, mice received a 0.5 × 0.5 cm full
thickness skin tail graft under general anesthesia. One donor
mouse produced grafts for 4 recipients. Grafts were secured
with Vaseline gauze and a bandage and sutured with 5-
6 sutures of 6–0 prolene in at least the four corners. Two
regimens of HBO therapy were used. In the first regimen,
HBO treated mice received 2 HBO sessions the day prior
to the skin grafting, one HBO session on the day of the
skin grafting followed by twice daily sessions 5 days every
week for total of 19 sessions. Each HBO session consisted
of 90 minutes exposure to 100% oxygen at 2.4 atmospheres
pressure. In this group, 4 mice were housed in one cage
at all times. In the second HBO therapy regimen, oxygen
pressure was increased to 300 kpa and mice received a total
of 29 sessions, including 10 sessions (2/day for 5 days) in
the week prior to skin grafting, one session during the day
of the skin graft followed by 2 sessions per day, 5 days per
week for 2 weeks. In the second HBO therapy group and
in the additional control group, each mouse was housed
in a separate cage to prevent potential overcrowding and
mechanical factors such as friction that may aﬀect skin
graft survival. The HBO chamber allows only 2 cages at
each session, therefore in both regimens, 4 mice shared one
cage during HBO therapy. Skin graft survival was assessed
daily by 2 separate examiners. Kaplan-Meier graphs were
constructed for graft survival and log-rank comparisons
of the groups were calculated. P < .05 was considered
statistically significant.
3. Results
Transplanted mice received 2 regimens of HBO therapy. In
the first regimen, among the 8 mice that received 19 courses
of HBO, skin graft was lost after 7.1 ± 1.4 days (range: 5–9
days), compared to graft loss after 8.4±1.7 days (range: 6–11
days) in themice that did not receive HBO therapy (P = .12).
In the second regimen, higher oxygen pressure (300 versus
240 kpa), increased number of HBO therapy sessions (29
versus 19 sessions), and reduced mice crowding (1 mouse
versus 4 mice per cage) were employed with the addition of 8
mice in each of the HBO treatment group and control group.
In the HBO therapy group, one mouse suﬀered a seizure-
like episode after 3 HBO sessions and was euthanized. In the
remaining HBO-treated mice, skin graft was rejected after
6.3 ± 2.4 days (range: 5–9 days) compared to 7.4 ± 1.6 days
(range: 4–11 days) in the control group (P = .32).
4. Discussion
To study the potential use of HBO therapy in modifying graft
rejection, we employed a well-recognized skin graft animal
model. In this study we found that HBO therapy as a sole
agent was not immunosuppressant enough to cause delay
in allo-skin graft rejection. Our experiment was repeated
twice to allow further testing of individual housing of mice
in order to prevent mechanical factors aﬀecting the graft
survival. Our attempts to increase oxygen pressure to 300 kpa
did not prolong graft survival, further suggesting that HBO
had no significant anti-inflammatory eﬀect in our model.
Moreover, one of the mice treated with the higher oxygen
pressure experienced a seizure episode.
Several investigators have reported the likely immuno-
suppressant eﬀect of HBO therapy. In 1979, Jacobs et al.
reported that a mouse ear composite allograft rejection
was significantly delayed by exposure to HBO therapy
[20]. Since then, many other investigators published similar
reports [21, 22]. However, after more than thirty years from
the original report, HBO therapy is not utilized for its
immunosuppressant eﬀect as a sole or an adjuvant agent
for human clinical use. That has raised some concerns
among clinicians and researchers alike regarding translating
these animal studies into human clinical use. Hence, our
experiment was designed to build up an animal model with
2 diﬀerent HBO atmospheric pressures, short or prolong
exposure to HBO along with the elimination of mechanical
factors such as friction by housing onemouse per cage for the
study and control mice, and if the animal model is successful,
then to try HBO therapy as an adjuvant agent for graft-
versus-host disease prophylaxis in very high risk patients
receiving unrelated hematopoietic stem cell transplantation.
However, there was no evidence of immunosuppression
in our mouse model. We hypothesize that HBO therapy
may be immunosuppressant by the diﬀerent mechanisms
described by others. However, the immune system is so
complex and includes many other factors and cytokine
signaling that may play a counter eﬀect. For example, HBO
may reduce CD4 : CD8 lymphocyte ratio [3] and decrease
lymphocyte proliferation [4] on one hand but increases
other cytokines or signaling eﬀects that may activate other
parts of the immune system with no resultant significant
immunosuppression on the other hand.
The beneficial eﬀect of HBO therapy in autologous graft-
ing or flaps in animals is remarkable, and it is clear that HBO
increases the tolerance of tissue to ischemia, increases the
viability of tissues, and helps in the early neovascularisation
[23–25]. The clinical applicability of HBO for composite
autografts has been reported by many other surgeons and,
most impressive of all, was the successful reimplantation
of a near-total amputation of the nose followed by HBO
therapy given twice daily in a 2-year-old girl [26], as was
the reimplantation of the tip of the nose after a dog bite
in a 5-year-old boy [27]. This potential which increases
ischemia tolerance and improves graft survival from the
autograft studies by HBO therapy was not noticeable in
our mouse skin allograft. Our hypothesis is that in our
skin allograft mouse model, the immune-mediated rejection
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and the resultant necrosis have masked the subtle potential
benefits of increasing tolerance to ischemia.
In conclusion, our data did not support the hypothesis
of HBO therapy as an eﬀective sole immunosuppressant
agent. Perhaps, HBO therapy may be immunosuppressant if
combined with other immunosuppressant agents rather than
a sole agent. Further research testing diﬀerent combinations
of immunosuppressant agents plus HBO is warranted.
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